Zymeworks Wins FDA Approval for Zanidatamab in Biliary Tract Cancer

Zymeworks Inc. (TSX: ZYME | NASDAQ: ZYME) secured a landmark U.S. Food and Drug Administration approval on October 29, 2026 for zanidatamab (brand name: Ziihera) as a second-line treatment for HER2-amplified biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder cancer. The approval covers adult patients whose disease has progressed on or after gemcitabine-based chemotherapy — a population estimated at roughly 12,000 eligible patients annually in the United States. The decision, granted under FDA’s accelerated approval pathway, converts a prior Breakthrough Therapy designation into a full commercial green light, marking the first bispecific antibody approved in this indication.

The Drug and Its Mechanism

Zanidatamab is a bispecific antibody that simultaneously binds two distinct epitopes on the HER2 receptor, driving superior receptor clustering and internalization compared with legacy HER2-targeting agents like trastuzumab. In the pivotal HERIZON-BTC-01 trial, zanidatamab demonstrated an objective response rate (ORR) of 41.3% with a median duration of response of 12.9 months in HER2-amplified BTC patients — outcomes that far exceed historical second-line response rates of 5–15% with standard chemotherapy. Grade 3 or higher adverse events occurred in 47% of patients, consistent with the class profile, with diarrhea and infusion-related reactions as the most common. The label carries no black-box warning, a meaningful commercial distinction versus older HER2-directed agents.

Market Opportunity and Competitive Landscape

Biliary tract cancers are rare but aggressive, with approximately 45,000 new cases diagnosed annually in the U.S. and Europe combined. HER2 amplification occurs in an estimated 15–20% of BTC cases, defining a molecularly selected sub-population that now has a validated targeted therapy. Analysts at Canaccord Genuity model peak annual sales for zanidatamab in BTC at USD $650 million (~CAD $913 million at the current 1.4047 rate), with upside contingent on label expansions into gastroesophageal junction cancer and breast cancer — both in Phase 3 trials. Key competitors include AstraZeneca’s trastuzumab deruxtecan (Enhertu), which is approved in HER2-positive gastric cancers but lacks a BTC-specific label, leaving zanidatamab with meaningful first-mover advantage in this niche.

Canadian Investor Angle and Stock Reaction

Zymeworks shares surged +38% in pre-market NASDAQ trading on the approval news, recovering a substantial portion of losses incurred after a 2022 strategic pivot that saw the company shed its partnership with Jazz Pharmaceuticals. The stock had been trading near CAD $22.40 on the TSX heading into October 29; the approval catalyst is expected to push it meaningfully above CAD $30 based on pre-market indicated pricing. For TSX-listed investors, the dual-listed structure ensures near-perfect price parity, though the stronger USD against CAD at 1.4047 provides a quiet tailwind — U.S.-dollar revenues will translate into larger CAD figures on Zymeworks’ Canadian financial statements.

Long-Term Thesis: Beyond Biliary Tract

The BTC approval is commercially meaningful but strategically, investors should watch the HERIZON-GEA-01 readout, expected in mid-2027, which tests zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma — a market ten times the size of BTC. A positive result there, combined with ongoing breast cancer studies, could reframe Zymeworks from a rare-cancer specialist into a broad HER2 franchise company. The broader biotech tape is constructive: XBI gained +1.72% to $157.51 and IBB rose +1.96% to $216.35 on October 29, suggesting risk appetite is supportive for small-cap biotech catalysts. Zymeworks carries roughly USD $380 million in cash, providing a runway that management says extends well past the GEA-01 readout without requiring dilutive financing — a critical comfort for retail shareholders wary of secondary offerings.